ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences has made a significant breakthrough in Alzheimer's research, showing that their drug PMN310 can reduce amyloid-beta oligomers in human cerebrospinal fluid, marking one of the first clinical trials to quantify such effects. This dose-dependent reduction, observed in healthy volunteers, suggests promising potential for the treatment of Alzheimer's disease. With the company set to unveil six-month data from its Phase 1b trial soon, this development could pave the way for more effective therapies targeting the disease's underlying mechanisms.